Click here for slides on this topic


Normoglycemia

A state of normal blood glucose concentration (also referred to as euglycemia).
The following content matched the glossary term: Normoglycemia

ORIGIN: Insulin Glargine and CVD and Other Outcomes in Dysglycemia

Top

Exclusive! Expert commentary from Silvio E. Inzucchi, MD, on the ORIGIN glargine trial. ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. ORIGIN: Insulin Glargine and CVD and Other Outcomes in Dysglycemia. N Engl J Med. 2012;367(4):319-328. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial is a randomized, double-blind trial with a 2X2 factorial design that enrolled 12,537 patients who were at high risk for CV events and who had IFG, IGT, or newly diagnosed diabetes

ORIGIN: Omega-3 Fatty Acid and CVD Outcomes in Patients with Dysglycemia

Top

Exclusive! Video commentary from Vivian A. Fonseca, MD. ORIGIN Trial Investigators, Bosch J, Gerstein HC, et al. ORIGIN: Omega-3 Fatty Acid and CVD Outcomes in Patients with Dysglycemia. N Engl J Med. 2012;367(4):309-318. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial is a randomized, double-blind trial with a 2X2 factorial design that enrolled 12,537 patients who were at high risk for CV events and who had IFG, IGT, or newly diagnosed diabetes.

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 11, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 11, 2012

ORIGIN trial results, insulin and cancer, TINSAL-T2D results, and more.

Clinical Insights in Diabetes Newsletter Archive

Top

Clinical Insights® in Diabetes Newsletter Archive

Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study

Top

Zinman B, Harris SB, Neuman J, Gerstein HC, Retnakaran RR, Raboud J, Qi Y, Hanley AJ. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet. 2010;376(9735):103-111. The evolving epidemic of type 2 diabetes has challenged health-care providers to assess the safety and efficacy of various diabetes prevention strategies. The CANOE (CAnadian Normoglycemia Outcomes Evaluation) trial investigated whether low-dose combination therapy would affect development of type 2 diabetes.

Serum uric acid levels improve prediction of incident type 2 diabetes in individuals with impaired fasting glucose: the Rancho Bernardo Study

Top

Kramer CK, von Mühlen D, Jassal SK, Barrett-Connor E. Serum uric acid levels improve prediction of incident type 2 diabetes in individuals with impaired fasting glucose: the Rancho Bernardo Study. Diabetes Care. 2009;32(7):1272-1273. To determine whether serum uric acid predicts incident type 2 diabetes by glucose tolerance status in older community-dwelling adults.

Approach to the management of diabetic patients with heart failure: role of thiazolidinediones

Top

Fonarow GC. Approach to the management of diabetic patients with heart failure: role of thiazolidinediones. Am Heart J. 2004;148:551-558. Diabetes mellitus is a chronic, progressive disease that results in microvascular and macrovascular complications.

Mode of Onset of Type 2 Diabetes from Normal or Impaired Glucose Tolerance

Top

Ferrannini E, Nannipieri M, Williams K, et al. Mode of Onset of Type 2 Diabetes from Normal or Impaired Glucose Tolerance. Diabetes. 2004;53:160-165. Fasting plasma glucose concentrations (FPG) predict development of type 2 diabetes. Whether hyperglycemia evolves from normoglycemia gradually over time or as a step increase is not known.

Gender Difference in All-Cause and Cardiovascular Mortality Related to Hyperglycemia and Newly Diagnosed Diabetes

Top

Hu G, The DECODE Study Group. Gender Difference in All-Cause and Cardiovascular Mortality Related to Hyperglycaemia and Newly-Diagnosed Diabetes Diabetologia. 2003;46:608-617. AIM/HYPOTHESIS: Diabetic women generally have a greater relative risk of cardiovascular diseases than diabetic men in comparison with non-diabetic women and men. Reasons for this excess risk in diabetic women is still unclear.

Risk of Diabetes in the New Diagnostic Category of Impaired Fasting Glucose

Top

Vaccaro O, Ruffa G, Imperatore G, Iovino V, Rivellese AA, Riccardi G. Risk of Diabetes in the New Diagnostic Category of Impaired Fasting Glucose. Diabetes Care. 1999;22:1490-1493. To prospectively evaluate progression to diabetes in individuals with impaired glucose regulation as defined according to fasting glucose alone or an oral glucose tolerance test (OGTT) (ie, both fasting and postload glucose) to compare the ability of these two screening methods to identify people at high risk of developing diabetes.

1 2 Next 

Slide Library Results

Search Results for: Normoglycemia Slides Found: 34
ACCORD-MIND: Relationship Between Glycemia Status, Diabetes Duration, and Cognitive Test Scores
ACCORD-MIND: Relationship Between Glycemia Status, CVD, Stroke, Smoking Status, and Cognitive Test Scores
Odds Ratios of In-Hospital Mortality by Admission and Fasting Glucose Levels
NICE-SUGAR: Blood Glucose Levels
NICE-SUGAR: Study Design
Indian Diabetes Prevention Programme-2: Results
ORIGIN Glargine Trial: Design
ORIGIN Glargine Trial: Primary and Secondary Outcomes
ORIGIN Glargine Trial: Eligibility Criteria and Trial Profile
ORIGIN Glargine Trial: Baseline Characteristics (1 of 2)
ORIGIN Glargine Trial: Baseline Characteristics (2 of 2)
ORIGIN Glargine Trial: Insulin Use During Trial
ORIGIN Glargine Trial: A1C, FPG During Trial
ORIGIN Glargine Trial: First Coprimary Composite CV Outcome—CV Death, Nonfatal MI, or Nonfatal Stroke
ORIGIN Glargine Trial: Second Coprimary Composite CV Outcome—CV Death, Nonfatal MI, Nonfatal Stroke, Revascularization, or Hospitalized Heart Failure
ORIGIN Glargine Trial: Secondary Outcomes
ORIGIN Glargine Trial: Secondary Outcome—Cancer Incidence
ORIGIN Glargine Trial: Hypoglycemia
ORIGIN Glargine Trial: Weight Change
ORIGIN Glargine Trial: Conclusions
ORIGIN Omega-3 Fatty Acid Trial: Design
ORIGIN Omega-3 Fatty Acid Trial: Primary and Secondary Outcomes
ORIGIN Omega-3 Fatty Acid Trial: Additional Outcomes
ORIGIN Omega-3 Fatty Acid Trial: Eligibility Criteria and Trial Profile
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (1 of 2)
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (2 of 2)
ORIGIN Omega-3 Fatty Acid Trial: Primary Outcome—CV Death
ORIGIN Omega-3 Fatty Acid Trial: Secondary Outcomes
ORIGIN Omega-3 Fatty Acid Trial: Mean Change in Lipids
ORIGIN Omega-3 Fatty Acid Trial: Conclusions
ORIGIN: Design
Glucose Monitoring SMBG CGM ADA Type 1 Diabetes Guidelines | NDEI
Hypoglycemia Management ADA Type 1 Diabetes Guidelines | NDEI
Metabolic Surgery Postoperative Follow-Up for Type 2 Diabetes Guidelines | NDEI